Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder
- 1 October 2017
- journal article
- research article
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 11 (1) , 56-60
Abstract
Objective: The aim of the present study was to prospectively evaluate the effect of aclatonium on dry mouth in patients with overactive bladder (OAB) after treatment with solifenacin.Methods: A multicenter randomized double‐blind controlled trial was conducted. The study subjects were men and women who had been diagnosed with OAB for ≥3 months and presented with a total Overactive Bladder Symptom Score (OABSS) ≥3. Eligible subjects were randomized to receive 5 mg solifenacin with placebo or 5 mg solifenacin with 150 mg aclatonium once daily for 8 weeks. Subjects rated dry mouth using a visual analog scale (VAS) and completed the OAB‐questionnaire (OAB‐q) short form (SF) and OABSS questionnaires at baseline and after 8 weeks treatment. Dry mouth was defined as a VAS score >30 points (range 0–100).Results: Overall, 92 patients (49 and 43 in the placebo and aclatonium groups, respectively) completed the 8‐week treatment. In patients who had dry mouth at baseline, no differences were detected in changes in the dry mouth VAS, OABSS, or OAB‐q SF scores between the 2 groups. However, in patients who had no dry mouth at baseline, the change in dry mouth VAS score was significantly lower in the aclatonium‐ than placebo‐treated group: the VAS score increased 20 points in the placebo group compared with 9 points in the aclatonium group (P = .03). However, there were no significant differences in changes in the OABSS and OAB‐q SF scores between the 2 groups.Conclusions: Aclatonium decreased dry mouth without disturbing treatment efficacy in patients who did not have dry mouth before treatment.Keywords
This publication has 19 references indexed in Scilit:
- Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trialInternational Journal Of Clinical Practice, 2014
- Long-Term Adherence to Antimuscarinic Therapy in Everyday Practice: A Systematic ReviewJournal of Urology, 2014
- Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladderInternational Journal Of Clinical Practice, 2014
- An overactive bladder symptom and health-related quality of life short-form: Validation of the OAB-q SFNeurourology and Urodynamics, 2014
- Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 TrialEuropean Urology, 2013
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- A review of adherence to drug therapy in patients with overactive bladderBJU International, 2008
- The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-AnalysisEuropean Urology, 2008
- Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom scoreUrology, 2006
- Stool Form Scale as a Useful Guide to Intestinal Transit TimeScandinavian Journal of Gastroenterology, 1997